| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15397 R63468 |
Chan - BZDs, 2023 | Autism spectrum disorder (ASD) - ICD-9-CM: 299 - Median follow-up time of 8.76 years | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) | 1.42 [1.06;1.90] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17870 R75493 |
Delteil - BZDs (Controls unexposed, NOS), 2023 | Pervasive developmental disorders (ICD-10: F84.0; F84.1; F84.5 and F84.8) - At 5 and/or 8 years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) |
1.33 [0.86;2.05] excluded (control group) |
23/2,183 481/72,294 | 504 | 2,183 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15610 R75485 |
Delteil - BZDs (Controls unexposed, sick), 2023 | Pervasive developmental disorders (ICD-10: F84.0; F84.1; F84.5 and F84.8) - At 5 and/or 8 years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) | 1.03 [0.50;2.14] | 23/2,183 11/1,179 | 34 | 2,183 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15459 R63562 |
Bjørk - Clonazepam (Mixed indications), 2022 | Diagnosis autism spectrum disorder (ASD): childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up clonazepam 9.5 (5.5-13.9) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: No (among antiseizure medications) | 1.43 [0.96;2.12] | 25/1,182 38,437/4,463,879 | 38,462 | 1,182 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15460 R63569 |
Chen - BZDs (Controls unexposed, NOS), 2022 | Autism spectrum disorder ASD (ICD-9 code 299; ICD-10 code F84) - At mean 8.5 (3.2) years. | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes BZD Coexposure: Not specified |
0.96 [0.89;1.03] excluded (control group) |
754/70,451 13,276/1,440,435 | 14,030 | 70,451 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15638 R64540 |
Chen - BZDs (Controls unexposed, sibling), 2022 | Autism spectrum disorder ASD (ICD-9 code 299; ICD-10 code F84) - At mean 8.5 (3.2) years. | 1st trimester | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes BZD Coexposure: Not specified |
0.92 [0.75;1.14] excluded (control group) |
-/26,652 -/29,233 | - | 26,652 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17008 R71235 |
Chen - BZDs (Controls unexposed, sick), 2022 | Autism spectrum disorder ASD (ICD-9 code 299; ICD-10 code F84) - At mean 8.5 (3.2) years. | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes BZD Coexposure: Not specified | 0.72 [0.60;0.87] | -/8,492 -/30,832 | - | 8,492 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15584 R64111 |
Coste - Clonazepam (Mixed indications), 2020 | Diagnosis Pervasive developmental disorders (F84) - Mean age follow-up 4.4 years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: No (among antiseizure medications) | 1.10 [0.50;2.10] | 8/1,246 4,280/1,710,441 | 4,288 | 1,246 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.10 [0.75;1.61] | 42,784 | 13,103 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Mixed indications; 3: Controls unexposed, sick; 4: Mixed indications;
Asymetry test p-value = 0.3413 (by Egger's regression)
slope=-0.3874 (0.3318); intercept=2.3416 (2.0756); t=1.1282; p=0.3413
excluded 15460, 15638, 17870